Skip to main content

MEDINET Co., Ltd. (2370.T)

Japan Exchange Group Healthcare BiotechnologyView data quality →
28.0Poor

ValueMarkers Composite Index

Top 0%#44,659 of 44,707

DCF data not available

Piotroski
2/9
Weak
Beneish
-1.05
High Risk
Altman
9.23
Safe
DCF Value
-
N/A
ROIC
-39.1%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

MEDINET Co., Ltd. (2370.T) — VMCI valuation read

MEDINET Co., Ltd. (2370.T) carries a VMCI composite of 28/100, 22 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 2370.T in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 2370.T insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 2370.T trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -0.7x leaves covenant headroom, the line to track on MEDINET Co., Ltd.'s next 10-Q.

2370.T rose 2.0% over the trailing 7 days, with a +4.1% read on a 30-day basis.

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.

CEO: Kanenao Kubushiro92 employeesJPwww.medinet-inc.co.jp

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 2370.T’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.